Skip to main content

Advertisement

Table 1 Patient demographic and baseline characteristics

From: Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients

Characteristic All Conventional chemotherapy PDX-guided chemotherapy OR (95% CI) P a
No. 57 45 12   
Female gender, n (%) 33 (57.89) 26 (57.78) 7 (58.33) 1.02 (0.28–3.72) 0.972
Age, years, n (%)
 < 65 23 (40.35) 18 (40) 5 (41.67) 1.07 (0.29–3.91) 0.917
Gallstone, n (%)
 Yes 44 (77.19) 36 (80) 8 (66.67) 0.5 (0.12–2.04) 0.555
CA19-9, U/mL, n (%)
 < 37 16 (28.07) 13 (28.89) 3 (25) 0.82 (0.19–3.52) 0.924
Tumor size, cm, n (%)
 < 4 37 (64.91) 31 (68.89) 6 (50) 0.45 (0.12–1.65) 0.223
Tumor differentiation, n (%)
 Well and moderate 31 (54.39) 23 (51.11) 8 (66.67) 1.91 (0.5–7.27) 0.525
Nerve invasion, n (%)
 Yes 21 (36.84) 15 (33.33) 6 (50) 0.5 (0.14–1.82) 0.288
Lymph node metastasis, n (%)
 Yes 21 (36.84) 14 (31.11) 7 (58.33) 0.4 (0.1–1.66) 0.375
bTNM stage, n (%)
 IIIA 36 (63.16) 31 (68.89) 5 (41.67) 0.32 (0.09–1.2) 0.082
 IIIB and IV 21 (36.84) 14 (31.11) 7 (58.33)
  1. PDX patient-derived xenograft
  2. aChi square test
  3. bTumor stage was defined according to the American Joint Committee on Cancer (AJCC) TNM staging system (AJCC 7th edition)